Desferal and Zosyn drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Desferal (deferoxamine mesylate) and Zosyn (piperacillin sodium; tazobactam sodium). Common drug interactions include abscess jaw among females and sepsis among males.

The phase IV clinical study analyzes what interactions people have when they take Desferal and Zosyn. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Desferal?

Desferal has active ingredients of deferoxamine mesylate. It is often used in iron overload. eHealthMe is studying from 2,248 Desferal users. Check the latest studies of Desferal.

What is Zosyn?

Zosyn has active ingredients of piperacillin sodium; tazobactam sodium. It is often used in pneumonia. eHealthMe is studying from 10,236 Zosyn users. Check the latest studies of Zosyn.



On Jul, 30, 2026

11 people who take Desferal and Zosyn together, and have interactions are studied.

Desferal and Zosyn drug interactions.

What are the common drug interactions of Desferal and Zosyn, by gender? *:

female:

  1. Abscess jaw (tooth abscess or root abscess)
  2. Alanine aminotransferase increased
  3. Aphthous stomatitis (mouth ulcer)
  4. Blood creatinine increased
  5. Blood urea increased
  6. Cellulitis (infection under the skin)
  7. Diarrhoea
  8. Disease progression
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Menorrhagia (an abnormally heavy bleeding and prolonged menstrual period at regular intervals)

male:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Urinary incontinence (inability to control the flow of urine and involuntary urination)
  3. Death
  4. Diarrhoea
  5. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  8. Prostatitis (inflammation of the prostate gland)
  9. Pyrexia (fever)
  10. Renal impairment (severely reduced kidney function)

What are the common drug interactions of Desferal and Zosyn, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Death

50-59:

  1. Abscess jaw (tooth abscess or root abscess)
  2. Alanine aminotransferase increased
  3. Aphthous stomatitis (mouth ulcer)
  4. Blood creatinine increased
  5. Blood urea increased
  6. Cellulitis (infection under the skin)
  7. Diarrhoea
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Pyrexia (fever)
  10. Renal impairment (severely reduced kidney function)

60+:

  1. Urinary incontinence (inability to control the flow of urine and involuntary urination)
  2. Bacterial infection
  3. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  4. Oedema due to cardiac disease (fluid collection in tissue due to heart disease)
  5. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  6. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
  7. Prostatitis (inflammation of the prostate gland)
  8. Sepsis (a severe blood infection that can lead to organ failure and death)
  9. Septic shock (shock due to blood infection)
  10. Urinary tract infection

What are the existing conditions these people have? *

  1. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 7 people, 63.64%
  2. Diabetes: 5 people, 45.45%
  3. Bacterial Infection: 3 people, 27.27%
  4. Septic Shock (shock due to blood infection): 3 people, 27.27%
  5. Sepsis (a severe blood infection that can lead to organ failure and death): 3 people, 27.27%
  6. Primary Myelofibrosis (primary disorder of the bone marrow): 3 people, 27.27%
  7. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 27.27%
  8. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 3 people, 27.27%
  9. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin): 3 people, 27.27%
  10. Enlarged Prostate: 3 people, 27.27%

* Approximation only. Some reports may have incomplete information.

Do you take Desferal and Zosyn?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Desferal and Zosyn:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Desferal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zosyn:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Desferal and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zosyn and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on deferoxamine mesylate and piperacillin sodium; tazobactam sodium (the active ingredients of Desferal and Zosyn, respectively), and Desferal and Zosyn (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: